Become a Market Leader
Industry Research Confirms the Challenges Facing Early-Stage MedTech
The commercialization challenges facing early-stage MedTech companies are well documented across academic research and industry analyses. Studies published through organizations such as the U.S. National Library of Medicine (PMC), MDPI, and ScienceDirect highlight persistent barriers including regulatory complexity, clinical evidence requirements, reimbursement uncertainty, and capital intensity. Industry reports and commentary from organizations including AdvaMed, Deloitte, RQM+, and MedCityNews further emphasize that many MedTech companies struggle not because the technology is weak, but because clinical validation, economic value, and commercialization strategies are often misaligned during the critical transition from innovation to market adoption.
At Steep Health, we focus on the critical stage where many promising healthcare technologies struggle to advance — the transition from innovation to commercialization.
Our work is grounded in the real-world challenges consistently identified across the MedTech ecosystem: clinical evidence generation, regulatory alignment, reimbursement strategy, economic value creation, enterprise health system adoption, and the development of scalable commercial infrastructure.
With more than 25 years of healthcare commercialization leadership, Steep Health Founder Steven Pusterla has helped organizations navigate complex healthcare markets and translate breakthrough technologies into scalable commercial success.
Steep Health partners with early-stage and growth-stage MedTech, HealthTech, AI, and healthcare data companies to build the strategies, partnerships, and commercial capabilities required to successfully bring innovation to market.